PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) shares dropped 1.2% during mid-day trading on Friday . The company traded as low as $0.7321 and last traded at $0.7588. Approximately 75,748 shares were traded during trading, an increase of 758% from the average session volume of 8,831 shares. The stock had previously closed at $0.7680.
PharmaCyte Biotech Price Performance
The business has a 50 day moving average of $0.75 and a 200 day moving average of $0.77.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Read More
- Five stocks we like better than PharmaCyte Biotech
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
